AstraZeneca has many subsidiaries, and the current agrochemical company Syngenta is just the tip of the iceberg.

Li Jun learned about Syngenta's current situation through the intelligence of his employees, and it is not completely controlled by the group company, but still has relatively independent powers!

Many group companies, even Li Jun's JuneYao Group, have many subsidiaries, why do they want to open so many subsidiaries, they all belong to a business under the group company?

This question goes to the heart of many business projects.

Corporate liability is limited to all its assets, shareholder liability is limited to its investment, a company intends to enter a new field, facing unknown risks, if you do not set up a subsidiary isolation, the whole company may be completely finished after the risk occurs, but if it is separated, then the business risk is separated, this is the first point.

The establishment of a subsidiary also facilitates accounting treatment.

Due to various taxes, most companies will whitewash their finances and make related accounts through the stories they control and other companies with special relationships, so as to dilute the tax burden and avoid taxes reasonably.

This maximizes the company's net profit.

In addition, various subsidiaries form different product lines and occupy different markets, Jingdong sells things, Lenovo sells computers, if Pepsi sells socks, most people will definitely think that this brand is fake, and the same product was originally sold at the high-end, and then you go to buy low-end, directly pull down the force, it is better to establish a subsidiary to develop the low-end market.

The establishment of a subsidiary, or a kind of division of the command level and independent authorization, the company's chain of command can not be too long, otherwise the command will fail, for many industries and senior talents, but also need relatively independent decision-making power, so the relevant departments will choose to separate, independent.

Subsidiaries can also carry out the transfer of high-quality assets, some companies if the main body is not good, the opening of a branch base can deal with the catastrophe faced by the main base, and some are to grasp high-quality assets in their hands, such as the later generation of Ma Yun Alipay will be independent, Ali's high-quality assets injection, because Alibaba's big investors are other investors such as Softbank, not other Ma Yun.

Some subsidiaries also have their own special point, that is, many subsidiaries are not completely controlled by the group, the management before the acquisition is still there, they also have a large number of shares, for the controlling shareholders, they are strategic investors, the management of the subsidiaries is not completely subordinate, but collaborators.

After getting the information of Syngenta, although Syngenta is small, it is not completely controlled by AstraZuneca Corporation, and its management holds a large number of shares, and AstraZeneca is only a strategic investor, although Syngenta is now small, but AstraZeneca holds only 40% of Syngenta's shares!

The decision-making power of the entire company is still in the hands of Syngenta's management!

They hold a controlling stake in Syngenta.

In other words, Li Jun has a chance.

Got Syngenta from Astra ReZeneca.

At that time, AstraZeneca invested less than $1 million in Syngenta and acquired a 40 percent stake.

Now that all these years have passed, Syngenta has appreciated in value, but its performance is obviously still minimal, and it has not yet reached the outbreak of later generations, and the take-off of Syngenta's entire business in later generations is still around 2000, so even if Syngenta appreciates, it is not much.

Li Jun's team made a valuation of Syngenta, and now Syngenta's maximum market value is about $10 million, and the Syngenta company invested in that year can give AstraZeneca almost five or six times the income, and its market value has reached almost five or six million US dollars.

With a valuation of more than 10 million yuan, whether AstraZeneca will sell its shares in Syngenta, or whether Syngenta's management will sell its shares again, their company has developed relatively well, but it has been stuck in a bottleneck for a long time, and even has a sense of confusion about the future business.

Because Syngenta currently does not have millions of dollars to throw on genetically modified crops, it is not Monsanto, although it is backed by Astra ReZeneca, but after all, people are stepmothers, and now they do not pay enough attention to Syngenta, and they have not increased their investment in Syngenta at all.

After the acquisition, it is basically left to fend for itself.

Therefore, this time, based on the current situation of his company, Li Jun directly bypassed AstraZeneca and issued an offer to Syngenta to acquire Syngenta.

In the face of the offer to Syngenta, some in Syngenta's management began to have ideas, and some of them wanted to cash out.

This was their reaction to the uncertainty about Syngenta's future, and AstraZeneca's stake in AstraZeneca did not lead to a substantial increase in the company's business, but only relatively, and the company did not change much.

The first offer was sent out, and Syngenta reacted violently.

Li Jun's second takeover offer came to Syngenta's management, and Li Jun could offer more to Syngenta, provided that Syngenta took back Astra ReZeneca's shares, took back Astra ReZeneca's shares, and their management sold some of their shares...... Li Jun will make a very lucrative offer for Syngenta.

The money for the acquisition of Syngenta shares held by AstraDeneca can be paid in advance.

As long as Syngenta's controlling stake does not participate in the company's management experience, this is Li Jun's promise to Syngenta's senior management that they can still hold a part of the company's shares, and then still have management rights over the company.

This second offer is attractive in many ways.

Management can make a profit again on most of its shares, and it will continue to have management rights over the company.

……

Lee's lucrative offer and Syngenta's current bleak prospects have made Syngenta's management excited, they haven't made money for too long, and Syngenta is going to be a dead company, and if they sell some of their shares, they will be able to make a fortune, because the person who made the bid is very generous, much more generous than Astra ReZeneca.

These managers, as long as they sell half of their shares, can all become millionaires all at once.

Millions of dollars, their mortgage and car loan are not a problem at all, and they can even pay off in unison There is still a lot of leftover, and the children's expenses for studying abroad are available.

From now on, there is no need to be anxious, they sell Syngenta at present, not all of them, because they still enjoy part of the equity and experience management rights, the company will do well in the future, they will still share the results in the future, if the company goes bankrupt later, then they are now cashing out, they are making a lot of money.

Rather than not seeing the future of Syngenta, it is better to settle most of the money now and gamble the rest.

This is for their current status quo

is the best choice.